Fremanezumab
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Fremanezumab: From Migraine Prevention to Migraine with Brainstem Aura
One-Sentence Summary
Fremanezumab is a humanised anti-CGRP monoclonal antibody with an established international role in preventing episodic and chronic migraine. The TxGNN model predicts it may also be effective for migraine with brainstem aura, a rare subtype historically excluded from pivotal trials, with no dedicated clinical trials but 20 supporting publications, mostly observational and preclinical.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available from Australian regulatory data (drug not TGA-registered); internationally established for episodic/chronic migraine prevention |
| Predicted New Indication | Migraine with brainstem aura |
| TxGNN Prediction Score | 99.94% |
| Evidence Level | L3 |
| Australia Market Status | Not marketed |
| Number of ARTG Entries | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, DrugBank-sourced mechanism-of-action text is not available (data gap). Based on the supporting literature, fremanezumab is a fully humanised IgG2Δa monoclonal antibody that selectively binds and neutralises calcitonin gene-related peptide (CGRP), a key mediator of trigeminovascular activation. This mechanism underlies its established use as a preventive treatment for episodic and chronic migraine.
Migraine with brainstem aura (formerly “basilar-type migraine”) is a migraine subtype in which aura symptoms originate from brainstem dysfunction. Because of theoretical concerns about vasoconstriction and cerebrovascular risk, this subtype has historically been excluded from the core Phase 3 trials of anti-CGRP antibodies, so direct evidence in this population is limited to case reports and small observational series rather than randomised data.
Mechanistically, the case for applicability is only moderate rather than decisive. Preclinical cortical spreading depression (CSD) models — CSD being the electrophysiological correlate of aura — show that fremanezumab does not fully block CSD propagation, only shortening the cortical recovery period. This suggests a plausible but partial biological rationale, consistent with the model’s high prediction score but limited real-world validation for this specific subtype.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 35268319 | 2022 | Case report/Review | J Clin Med | Reviews case reports and literature on anti-CGRP mAbs (including fremanezumab) for preventing migraine aura; efficacy on headache pain is well documented but aura-specific data remain scarce |
| 40264646 | 2025 | Case report/Review | Frontiers in Neurology | Case report and literature review on anti-CGRP mAb efficacy in hemiplegic migraine, a rare aura subtype generally excluded from RCTs |
| 41618146 | 2026 | Individual patient analysis | J Headache Pain | Quantitative analysis of anti-CGRP mAb effectiveness/safety in hemiplegic migraine, noting systematic RCT exclusion of this population |
| 38332541 | 2024 | Observational case series | CNS Neurosci Ther | Evaluates anti-CGRP-targeted therapy effect specifically on migraine aura; notes limited clinical evidence base |
| 35302681 | 2022 | Cohort (post hoc, FOCUS study) | Eur J Neurol | Post hoc analysis of fremanezumab in difficult-to-treat migraine, including subgroups with and without aura/neurological dysfunction |
| 35775208 | 2022 | Cohort | Cephalalgia | Evaluates effects of erenumab, fremanezumab and galcanezumab on prodromal, accompanying, and central migraine symptoms |
| 37555331 | 2023 | Real-world cohort | Cephalalgia | Real-world evidence on anti-CGRP mAb impact on migraine accompanying symptoms, an area poorly studied in trials |
| 31127003 | 2019 | Preclinical (animal CSD model) | J Neurosci | Fremanezumab did not affect CSD-induced arterial dilatation or plasma protein extravasation, questioning CGRP’s role in the vascular component of aura |
| 31895266 | 2020 | Preclinical (animal CSD model) | Pain | Fremanezumab slowed CSD propagation rate and shortened cortical recovery but did not prevent CSD occurrence |
| 30725283 | 2019 | Review | Handb Exp Pharmacol | General review of CGRP’s role in migraine pathophysiology, including the aura-associated CNS dysfunction hypothesis |
Australia Market Information
Fremanezumab is not currently registered on the Australian Register of Therapeutic Goods (ARTG) — 0 entries were found, and no Australian product information is available.
Safety Considerations
No Australian safety data (warnings, contraindications, or drug interactions) is currently available. As fremanezumab is not TGA-registered, no Australian Product Information exists; prescribers should consult the manufacturer’s overseas-approved product information (e.g. FDA or EMA label) for safety guidance until local registration occurs.
Conclusion and Next Steps
Decision: Hold
Rationale: Fremanezumab is not registered in Australia (0 ARTG entries, no local PI), and evidence for migraine with brainstem aura specifically is limited to observational/case-level data and preclinical CSD models (L3) — with no dedicated RCTs, reflecting this subtype’s historical exclusion from pivotal trials over theoretical vasoconstriction concerns.
To proceed, the following is needed:
- TGA registration / ARTG listing and access to Australian Product Information
- Dedicated prospective efficacy and safety data in migraine with brainstem aura, given the theoretical cerebrovascular risk relevant to this subtype
- Formal DrugBank/PI-sourced mechanism-of-action and drug-interaction data (currently data gaps DG001, DG002)
- TGA-equivalent safety warnings and contraindications review before any clinical evaluation proceeds
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.